vemurafenib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
Raf (Rapidely Accelerated Fibrosarcoma) kinase inhibitors	4185	918504-65-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: PLX-4032 RO 5185426 RG 7204 vemurafenib zelboraf Ro 51-85426	Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serine- threonine kinase, including BRAF V600E. Vemurafenib also inhibits other kinases in vitro such as CRAF, ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5, and FGR at similar concentrations. Some mutations in the BRAF gene including V600E result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation. Vemurafenib has anti-tumor effects in cellular and animal models of melanomas with mutated BRAF V600E. Molecular weight: 489.92 Formula: C23H18ClF2N3O3S CLOGP: 4.57 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 91.92 ALOGS: -6.13 ROTB: 6 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

PLX-4032
RO 5185426
RG 7204
vemurafenib
zelboraf
Ro 51-85426

Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serine- threonine kinase, including BRAF V600E. Vemurafenib also inhibits other kinases in vitro such as CRAF, ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5, and FGR at similar concentrations. Some mutations in the BRAF gene including V600E result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation. Vemurafenib has anti-tumor effects in cellular and animal models of melanomas with mutated BRAF V600E.

Molecular weight: 489.92
Formula: C23H18ClF2N3O3S
CLOGP: 4.57
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 91.92
ALOGS: -6.13
ROTB: 6

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.92	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Aug. 17, 2011	FDA	HOFFMANN LA ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rash	314.19	25.57	386	8459	560485	62919692
Disease progression	313.32	25.57	201	8644	122557	63357620
Photosensitivity reaction	239.95	25.57	87	8758	14907	63465270
Metastases to central nervous system	239.83	25.57	84	8761	13021	63467156
Keratoacanthoma	209.28	25.57	39	8806	444	63479733
Rash maculo-papular	179.60	25.57	88	8757	31808	63448369
Sunburn	174.13	25.57	46	8799	2742	63477435
Drug reaction with eosinophilia and systemic symptoms	168.82	25.57	86	8759	33750	63446427
Skin toxicity	167.42	25.57	50	8795	4664	63475513
Squamous cell carcinoma	145.22	25.57	52	8793	8580	63471597
Hyperkeratosis	131.20	25.57	44	8801	5974	63474203
Skin papilloma	127.12	25.57	41	8804	4928	63475249
Erythema multiforme	108.70	25.57	44	8801	10125	63470052
Pyrexia	108.43	25.57	216	8629	470262	63009915
Arthralgia	97.56	25.57	232	8613	569478	62910699
Melanocytic naevus	94.47	25.57	32	8813	4476	63475701
Blood lactate dehydrogenase increased	90.47	25.57	50	8795	23066	63457111
Death	86.21	25.57	172	8673	374209	63105968
Electrocardiogram QT prolonged	85.69	25.57	69	8776	59461	63420716
Chorioretinopathy	82.99	25.57	20	8825	819	63479358
Squamous cell carcinoma of skin	81.24	25.57	31	8814	6101	63474076
Uveitis	80.81	25.57	38	8807	12515	63467662
Toxic skin eruption	70.82	25.57	35	8810	12850	63467327
Mass	68.07	25.57	35	8810	13965	63466212
Erythema	65.52	25.57	100	8745	175651	63304526
Metastatic malignant melanoma	64.78	25.57	18	8827	1297	63478880
Neutrophilic panniculitis	54.47	25.57	9	8836	47	63480130
Keratosis pilaris	54.15	25.57	9	8836	49	63480128
Stevens-Johnson syndrome	54.05	25.57	37	8808	24913	63455264
Solar dermatitis	51.73	25.57	10	8835	140	63480037
Serous retinal detachment	48.14	25.57	11	8834	356	63479821
Drug ineffective	45.98	25.57	47	8798	1044718	62435459
Panniculitis	45.56	25.57	25	8820	11360	63468817
Diarrhoea	44.63	25.57	207	8638	715159	62765018
Malignant neoplasm progression	42.91	25.57	55	8790	82066	63398111
Drug eruption	42.83	25.57	34	8811	28660	63451517
Decreased appetite	42.40	25.57	102	8743	250950	63229227
Papilloma	40.58	25.57	9	8836	254	63479923
Condition aggravated	39.10	25.57	5	8840	402212	63077965
Retinal detachment	38.20	25.57	18	8827	5951	63474226
Face oedema	36.88	25.57	27	8818	20185	63459992
Acrochordon	36.45	25.57	11	8834	1061	63479116
Erythema nodosum	35.24	25.57	16	8829	4859	63475318
Dermatitis acneiform	34.87	25.57	16	8829	4980	63475197
Decreased activity	34.22	25.57	17	8828	6303	63473874
Dermatitis exfoliative	33.52	25.57	16	8829	5443	63474734
Radiation skin injury	33.46	25.57	10	8835	933	63479244
Dysphagia	32.38	25.57	50	8795	88535	63391642
Enanthema	31.29	25.57	8	8837	418	63479759
Myalgia	29.65	25.57	64	8781	146465	63333712
Malignant melanoma in situ	29.28	25.57	9	8836	923	63479254
Dermatitis exfoliative generalised	29.13	25.57	13	8832	3794	63476383
Fall	27.79	25.57	10	8835	392324	63087853
Hepatocellular injury	27.74	25.57	26	8819	27355	63452822
Impaired work ability	26.70	25.57	21	8824	17454	63462723

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rash	456.17	24.43	439	10180	222313	34723999
Disease progression	447.69	24.43	321	10298	107756	34838556
Photosensitivity reaction	392.30	24.43	140	10479	10454	34935858
Sunburn	338.71	24.43	84	10535	1739	34944573
Metastases to central nervous system	268.44	24.43	99	10520	8106	34938206
Hyperkeratosis	195.17	24.43	64	10555	3685	34942627
Skin papilloma	190.83	24.43	55	10564	2048	34944264
Keratoacanthoma	162.14	24.43	38	10581	612	34945700
Squamous cell carcinoma	158.89	24.43	75	10544	11400	34934912
Alopecia	152.70	24.43	94	10525	24261	34922051
Skin toxicity	142.80	24.43	54	10565	4730	34941582
Arthralgia	138.80	24.43	211	10408	169830	34776482
Uveitis	97.42	24.43	47	10572	7488	34938824
Keratosis pilaris	92.97	24.43	17	10602	70	34946242
Pyrexia	90.69	24.43	263	10356	332750	34613562
Rash maculo-papular	87.35	24.43	71	10548	28380	34917932
Melanocytic naevus	86.74	24.43	31	10588	2313	34943999
Squamous cell carcinoma of skin	68.15	24.43	42	10577	10839	34935473
Dermatitis acneiform	66.36	24.43	34	10585	6155	34940157
Chorioretinopathy	63.87	24.43	22	10597	1471	34944841
Mass	61.23	24.43	35	10584	7870	34938442
Malignant melanoma	57.83	24.43	34	10585	8056	34938256
Blood lactate dehydrogenase increased	53.53	24.43	49	10570	22941	34923371
Iridocyclitis	50.56	24.43	19	10600	1633	34944679
Retinopathy	49.90	24.43	20	10599	2044	34944268
Drug reaction with eosinophilia and systemic symptoms	48.73	24.43	55	10564	32957	34913355
Intentional product use issue	48.23	24.43	74	10545	59742	34886570
Death	46.82	24.43	241	10378	397808	34548504
Serous retinal detachment	46.70	24.43	14	10605	598	34945714
Decreased appetite	46.54	24.43	133	10486	166259	34780053
Retinal detachment	44.80	24.43	25	10594	5366	34940946
Poor quality sleep	44.53	24.43	29	10590	8227	34938085
Neoplasm	44.48	24.43	25	10594	5442	34940870
Fatigue	43.27	24.43	224	10395	370429	34575883
Erythema	42.04	24.43	87	10532	88693	34857619
Dysphagia	41.86	24.43	71	10548	62310	34884002
Metastatic malignant melanoma	39.81	24.43	17	10602	2038	34944274
Rash follicular	39.29	24.43	7	10612	24	34946288
Impaired work ability	38.99	24.43	25	10594	6905	34939407
Dysgeusia	38.85	24.43	44	10575	26453	34919859
Solar dermatitis	38.81	24.43	8	10611	68	34946244
Skin reaction	37.43	24.43	22	10597	5208	34941104
Diarrhoea	35.16	24.43	220	10399	389692	34556620
No adverse event	33.49	24.43	38	10581	22889	34923423
Decreased activity	32.84	24.43	19	10600	4368	34941944
Acne	32.64	24.43	27	10592	11039	34935273
Hepatotoxicity	32.04	24.43	36	10583	21449	34924863
Panniculitis	30.58	24.43	14	10605	1980	34944332
Myalgia	30.35	24.43	74	10545	84036	34862276
Hyperthyroidism	29.55	24.43	25	10594	10541	34935771
Pruritus	28.23	24.43	101	10518	141880	34804432
Skin hypopigmentation	27.74	24.43	8	10611	298	34946014
Condition aggravated	27.50	24.43	12	10607	192184	34754128
Skin mass	26.53	24.43	16	10603	3969	34942343
Toxic skin eruption	25.97	24.43	24	10595	11361	34934951
Blood creatine phosphokinase increased	24.87	24.43	47	10572	44810	34901502
Serous retinopathy	24.81	24.43	6	10613	111	34946201

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Photosensitivity reaction	502.34	21.08	178	14943	20949	79708318
Rash	496.37	21.08	576	14545	577782	79151485
Disease progression	333.26	21.08	277	14844	184085	79545182
Keratoacanthoma	317.70	21.08	66	15055	979	79728288
Sunburn	278.30	21.08	76	15045	3757	79725510
Rash maculo-papular	277.03	21.08	157	14964	55921	79673346
Hyperkeratosis	265.24	21.08	86	15035	7704	79721563
Skin toxicity	255.74	21.08	85	15036	8229	79721038
Squamous cell carcinoma	220.46	21.08	90	15031	15532	79713735
Pyrexia	187.08	21.08	402	14719	678307	79050960
Drug reaction with eosinophilia and systemic symptoms	180.99	21.08	126	14995	64118	79665149
Skin papilloma	160.58	21.08	55	15066	5831	79723436
Uveitis	149.50	21.08	70	15051	16760	79712507
Keratosis pilaris	144.14	21.08	22	15099	39	79729228
Melanocytic naevus	135.98	21.08	46	15075	4695	79724572
Metastases to central nervous system	135.92	21.08	65	15056	16310	79712957
Chorioretinopathy	133.39	21.08	38	15083	2193	79727074
Arthralgia	128.65	21.08	313	14808	571490	79157777
Squamous cell carcinoma of skin	123.51	21.08	58	15063	13975	79715292
Serous retinal detachment	96.42	21.08	25	15096	1009	79728258
Retinal detachment	96.39	21.08	43	15078	9204	79720063
Dermatitis acneiform	87.00	21.08	41	15080	9952	79719315
Toxic skin eruption	77.82	21.08	50	15071	22243	79707024
Erythema multiforme	75.34	21.08	45	15076	17606	79711661
Neutrophilic panniculitis	73.29	21.08	13	15108	77	79729190
Death	71.86	21.08	253	14868	566261	79163006
Solar dermatitis	71.71	21.08	15	15106	230	79729037
Erythema	71.29	21.08	141	14980	223149	79506118
Panniculitis	67.44	21.08	37	15084	12334	79716933
Diarrhoea	66.91	21.08	336	14785	880153	78849114
Retinopathy	60.33	21.08	24	15097	3867	79725400
Papilloma	60.07	21.08	14	15107	360	79728907
Iridocyclitis	57.96	21.08	23	15098	3681	79725586
Blood creatine phosphokinase increased	57.95	21.08	67	15054	66023	79663244
Condition aggravated	56.39	21.08	13	15108	501111	79228156
Malignant neoplasm progression	56.14	21.08	96	15025	135894	79593373
Electrocardiogram QT prolonged	55.95	21.08	77	15044	90309	79638958
Radiation skin injury	53.58	21.08	17	15104	1417	79727850
Stevens-Johnson syndrome	52.83	21.08	50	15071	39116	79690151
Drug ineffective	50.22	21.08	80	15041	1080833	78648434
Erythema nodosum	49.95	21.08	23	15098	5294	79723973
Decreased appetite	48.63	21.08	159	14962	342259	79387008
Malignant melanoma	46.41	21.08	31	15090	14710	79714557
Hyperthyroidism	43.36	21.08	35	15086	22174	79707093
Cholestasis	42.64	21.08	51	15070	52058	79677209
Metastatic malignant melanoma	42.10	21.08	17	15104	2846	79726421
Face oedema	41.98	21.08	38	15083	28098	79701169
Seborrhoeic keratosis	41.68	21.08	16	15105	2344	79726923
Hepatocellular injury	41.30	21.08	48	15073	47545	79681722
Ejection fraction decreased	40.75	21.08	41	15080	34536	79694731
Dermatitis exfoliative	39.56	21.08	25	15096	10804	79718463
Fall	39.04	21.08	22	15099	487607	79241660
Dysgeusia	38.86	21.08	51	15070	57126	79672141
Dizziness	36.40	21.08	28	15093	526413	79202854
Weight increased	35.91	21.08	5	15116	277381	79451886
Hepatotoxicity	35.20	21.08	46	15075	51306	79677961
Alopecia	35.13	21.08	110	15011	231245	79498022
Drug hypersensitivity	35.12	21.08	7	15114	298909	79430358
Gamma-glutamyltransferase increased	34.45	21.08	47	15074	54633	79674634
Myalgia	33.65	21.08	94	15027	185547	79543720
Acute kidney injury	33.61	21.08	190	14931	519214	79210053
Rash follicular	33.30	21.08	7	15114	110	79729157
Radiation necrosis	33.11	21.08	9	15112	436	79728831
Mass	32.98	21.08	27	15094	17445	79711822
Skin exfoliation	32.67	21.08	46	15075	55054	79674213
Panniculitis lobular	32.36	21.08	6	15115	47	79729220
Sarcoidosis	32.35	21.08	20	15101	8315	79720952
Dry skin	32.07	21.08	51	15070	67944	79661323
Serous retinopathy	31.08	21.08	7	15114	154	79729113
Dermatitis	30.25	21.08	28	15093	21293	79707974
Infusion related reaction	30.15	21.08	4	15117	230233	79499034
Blood creatinine increased	29.57	21.08	80	15041	154977	79574290
Drug eruption	29.56	21.08	39	15082	43896	79685371
Dermal cyst	29.42	21.08	13	15108	2719	79726548
Blood pressure increased	29.35	21.08	3	15118	211357	79517910
Renal failure	28.18	21.08	93	15028	200875	79528392
Skin mass	27.92	21.08	18	15103	8045	79721222
Rash papular	27.70	21.08	27	15094	21889	79707378
Nasopharyngitis	27.70	21.08	7	15114	253874	79475393
Malignant melanoma in situ	27.48	21.08	12	15109	2440	79726827
Intracranial tumour haemorrhage	27.05	21.08	8	15113	527	79728740
Product dose omission issue	26.67	21.08	7	15114	247530	79481737
Skin reaction	26.55	21.08	23	15098	16045	79713222
Palmar-plantar erythrodysaesthesia syndrome	26.40	21.08	32	15089	33102	79696165
Joint swelling	26.15	21.08	11	15110	288635	79440632
Metastases to meninges	25.99	21.08	13	15108	3588	79725679
Metastasis	25.42	21.08	16	15105	6864	79722403
Epidermal naevus syndrome	25.27	21.08	4	15117	10	79729257
BRAF gene mutation	24.89	21.08	5	15116	62	79729205
Toxicity to various agents	24.83	21.08	26	15095	421514	79307753
Transaminases increased	24.66	21.08	39	15082	51704	79677563
Milia	23.88	21.08	5	15116	77	79729190
Blood alkaline phosphatase increased	23.73	21.08	43	15078	63621	79665646
Vogt-Koyanagi-Harada disease	23.12	21.08	6	15115	243	79729024
Rash erythematous	22.79	21.08	40	15081	57729	79671538
Pancreatitis	22.67	21.08	44	15077	68531	79660736
Dysphagia	22.26	21.08	62	15059	122074	79607193
Dermatitis exfoliative generalised	22.25	21.08	15	15106	7226	79722041
Acantholysis	22.23	21.08	4	15117	26	79729241
Skin hypopigmentation	22.17	21.08	8	15113	987	79728280
Superficial spreading melanoma stage unspecified	22.05	21.08	6	15115	292	79728975
Abdominal discomfort	22.00	21.08	10	15111	250717	79478550
Rash morbilliform	21.97	21.08	14	15107	6136	79723131
General physical health deterioration	21.39	21.08	106	15015	275132	79454135
Eosinophilia	21.36	21.08	34	15087	45311	79683956
Neoplasm	21.34	21.08	16	15105	9100	79720167
Fatigue	21.25	21.08	269	14852	929458	78799809
Hepatitis	21.23	21.08	38	15083	55689	79673578
Recall phenomenon	21.13	21.08	8	15113	1129	79728138
Skin disorder	21.11	21.08	29	15092	33914	79695353

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EC01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS B-Raf serine-threonine kinase (BRAF) inhibitors
FDA MoA	N0000175076	Protein Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
FDA MoA	N0000182138	Cytochrome P450 1A2 Inhibitors
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:75047	BRAF inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Erdheim-Chester Disease	indication	699537002	DOID:4329
Malignant Melanoma with BRAF V600E Mutation	indication	830150003
Hypocalcemia	contraindication	5291005
Hyperbilirubinemia	contraindication	14783006	DOID:2741
Torsades de pointes	contraindication	31722008
Hypokalemia	contraindication	43339004
Bradycardia	contraindication	48867003
Acute nephropathy	contraindication	58574008
Iritis	contraindication	65074000	DOID:1406
Prolonged QT interval	contraindication	111975006
Uveitis	contraindication	128473001	DOID:13141
Liver function tests abnormal	contraindication	166603001
Hypomagnesemia	contraindication	190855004
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001
Decompensated chronic heart failure	contraindication	424404003
Congenital long QT syndrome	contraindication	442917000
Retinal Blood Vessel Occlusions	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.98	acidic
pKa2	13.65	acidic
pKa3	4.56	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
240MG	ZELBORAF	HOFFMANN LA ROCHE	N202429	Aug. 17, 2011	RX	TABLET	ORAL	8470818	Aug. 2, 2026	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST
240MG	ZELBORAF	HOFFMANN LA ROCHE	N202429	Aug. 17, 2011	RX	TABLET	ORAL	8470818	Aug. 2, 2026	ZELBORAF IS INDICATED FOR THE TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
240MG	ZELBORAF	HOFFMANN LA ROCHE	N202429	Aug. 17, 2011	RX	TABLET	ORAL	Nov. 6, 2024	TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Serine/threonine-protein kinase B-raf	Kinase	P15056	BRAF_HUMAN	INHIBITOR	IC50	7.68	CHEMBL	CHEMBL
RAF proto-oncogene serine/threonine-protein kinase	Kinase	P04049	RAF1_HUMAN		IC50	7.32	CHEMBL
Vascular endothelial growth factor receptor 2	Kinase	P35968	VGFR2_HUMAN		IC50	6.44	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5	Kinase	Q9Y4K4	M4K5_HUMAN		Kd	5.75	CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	6.37	CHEMBL
TGF-beta receptor type-2	Kinase	P37173	TGFR2_HUMAN		Kd	5.47	CHEMBL
Protein-tyrosine kinase 6	Kinase	Q13882	PTK6_HUMAN		Kd	5.85	CHEMBL
Mitogen-activated protein kinase kinase kinase MLT	Kinase	Q9NYL2	MLTK_HUMAN		IC50	7.64	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	6.13	CHEMBL
Serine/threonine-protein kinase A-Raf	Kinase	P10398	ARAF_HUMAN		IC50	6.02	CHEMBL
GTPase KRas	Enzyme	P01116	RASK_HUMAN		IC50	4.78	CHEMBL
Ferrochelatase, mitochondrial	Enzyme	P22830	HEMH_HUMAN		EC50	5.30	CHEMBL
Receptor-interacting serine/threonine-protein kinase 3	Kinase	Q9Y572	RIPK3_HUMAN		Kd	5.68	CHEMBL
Aspartyl/asparaginyl beta-hydroxylase	Enzyme	Q12797	ASPH_HUMAN		IC50	4.98	CHEMBL
Serine/threonine-protein kinase B-raf	Kinase		BRAF_MOUSE		IC50	7.52	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4	Unclassified		MP2K4_MOUSE		Kd	8.09	CHEMBL

External reference:

ID	Source
4030980	VUID
N0000183250	NUI
D09996	KEGG_DRUG
4030980	VANDF
C3192263	UMLSCUI
CHEBI:63637	CHEBI
032	PDB_CHEM_ID
CHEMBL1229517	ChEMBL_ID
D000077484	MESH_DESCRIPTOR_UI
DB08881	DRUGBANK_ID
5893	IUPHAR_LIGAND_ID
9286	INN_ID
207SMY3FQT	UNII
42611257	PUBCHEM_CID
1147220	RXNORM
185260	MMSL
28057	MMSL
d07798	MMSL
013887	NDDF
702805007	SNOMEDCT_US
703656005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ZELBORAF	HUMAN PRESCRIPTION DRUG LABEL	1	50242-090	TABLET, FILM COATED	240 mg	ORAL	NDA	29 sections
ZELBORAF	HUMAN PRESCRIPTION DRUG LABEL	1	50242-090	TABLET, FILM COATED	240 mg	ORAL	NDA	29 sections